These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12853744)

  • 1. Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration.
    Porcellini S; Vallanti G; Nozza S; Poli G; Lazzarin A; Tambussi G; Siccardi AG; Grassi F
    AIDS; 2003 Jul; 17(11):1621-30. PubMed ID: 12853744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune).
    Pido-Lopez J; Burton C; Hardy G; Pires A; Sullivan A; Gazzard B; Aspinall R; Gotch F; Imami N
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):103-9. PubMed ID: 12639245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
    Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
    Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.
    Wendland T; Furrer H; Vernazza PL; Frutig K; Christen A; Matter L; Malinverni R; Pichler WJ
    AIDS; 1999 Oct; 13(14):1857-62. PubMed ID: 10513643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART).
    Ruiz-Mateos E; Rubio A; Vallejo A; De la Rosa R; Sanchez-Quijano A; Lissen E; Leal M
    Clin Exp Immunol; 2004 Jun; 136(3):501-6. PubMed ID: 15147352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.
    Stapleton JT; Chaloner K; Zhang J; Klinzman D; Souza IE; Xiang J; Landay A; Fahey J; Pollard R; Mitsuyasu R
    AIDS; 2009 Mar; 23(5):605-10. PubMed ID: 19194270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART.
    Martinez-Mariño B; Shiboski S; Hecht FM; Kahn JO; Levy JA
    AIDS; 2004 Oct; 18(15):1991-9. PubMed ID: 15577620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
    Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
    HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
    Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
    AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
    Dybul M; Hidalgo B; Chun TW; Belson M; Migueles SA; Justement JS; Herpin B; Perry C; Hallahan CW; Davey RT; Metcalf JA; Connors M; Fauci AS
    J Infect Dis; 2002 Jan; 185(1):61-8. PubMed ID: 11756982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART.
    Sutherland R; Yang H; Scriba TJ; Ondondo B; Robinson N; Conlon C; Suttill A; McShane H; Fidler S; McMichael A; Dorrell L
    AIDS; 2006 Apr; 20(6):821-9. PubMed ID: 16549965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases in CD4+ T lymphocytes occur without increases in thymic size in HIV-infected subjects receiving interleukin-2 therapy.
    Lu AC; Jones EC; Chow C; Miller KD; Herpin B; Rock-Kress D; Metcalf JA; Lane HC; Kovacs JA
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):299-303. PubMed ID: 14600575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia.
    Rallón N; Sempere-Ortells JM; Soriano V; Benito JM
    J Antimicrob Chemother; 2013 Nov; 68(11):2616-25. PubMed ID: 23833186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.